

Draft Guide to the 2007 Dialysis Facility Reports:

Overview, Methodology, and Interpretation

July 2007

Guide to the 2007 Dialysis Facility Reports for Dialysis Patients: Overview, Methodology, and Interpretation

Table of Contents

I. PURPOSE OF THIS GUIDE AND THE DIALYSIS FACILITY REPORTS	1
“ <i>What’s New</i> ”	1
II. OVERVIEW.....	1
III. ASSIGNING PATIENTS TO FACILITIES	3
<i>General Inclusion Criteria for Dialysis Patients</i>	3
<i>Identifying Patients Treated at Each Facility (see also Section XIII)</i>	4
IV. MORTALITY SUMMARY FOR ALL DIALYSIS PATIENTS, 2003-2006	4
<i>Patients (1a)</i>	5
<i>Patient Years at Risk (1b)</i>	5
<i>Deaths (1c)</i>	5
<i>Expected Deaths (1d)</i>	6
<i>Death Rate per 100 Patient Years (1e)</i>	6
<i>Expected Death Rate per 100 Patient Years (1f)</i>	6
<i>Categories of Death (1g, 1h, 1i)</i>	6
<i>Standardized Mortality Ratio (SMR) (1j)</i>	7
<i>P-value (1k)</i>	8
<i>Confidence Interval for SMR (1l)</i>	9
<i>SMR Percentiles for This Facility (1m, 1n, 1o)</i>	9
V. HOSPITALIZATION SUMMARY FOR MEDICARE DIALYSIS PATIENTS, 2003-2005.....	10
<i>Medicare Dialysis Patients (2a)</i>	11
<i>Patient Years at Risk (2b)</i>	11
<i>Patient Years at Risk for Total Admissions (2c)</i>	11
<i>Total Admissions (2d)</i>	11
<i>Expected Total Admissions (2e)</i>	11
<i>Observed Admission Rate per 100 Patient Years (2f)</i>	12
<i>Expected Admission Rate per 100 Patient Years (2g)</i>	12
<i>Standardized Total Admission Ratio (2h)</i>	12
<i>Diagnoses Present at Admission (2i, 2j)</i>	12
<i>Average Length of Stay (2k)</i>	12
<i>One Day Admissions (2l)</i>	13
<i>Average Days in the Hospital per Dialysis Patient Year (2m)</i>	13
VI. TRANSPLANTATION SUMMARY FOR DIALYSIS PATIENTS UNDER AGE 70 WHO HAVE NOT PREVIOUSLY RECEIVED A TRANSPLANT, 2003-2006	13
<i>Eligible Patients (3a)</i>	14
<i>Patient Years at Risk (3b)</i>	14
<i>Actual First Transplants (3c)</i>	14

<i>Expected First Transplants (3d)</i>	14
<i>First Transplant Rate per 100 Patient Years (3e)</i>	14
<i>Expected First Transplant Rate per 100 Patient Years at Risk (3f)</i>	15
<i>Number of Deceased Donor Transplants (3g)</i>	15
<i>Standardized Transplantation Ratio (3h)</i>	15
<i>P-value (3i)</i>	15
<i>Confidence Intervals for STR (3j)</i>	16
<i>STR Percentile for This Facility (3k, 3l, 3m)</i>	16
VII. WAITLIST SUMMARY FOR DIALYSIS PATIENTS UNDER AGE 70 TREATED AS OF DECEMBER 31 OF EACH YEAR, 2003-2006	16
<i>Eligible Patients on 12/31 (4a)</i>	16
<i>Patients on the Waitlist (4b)</i>	16
<i>P-value (4c)</i>	16
<i>Patient Characteristics (4d-4e)</i>	17
VIII. FACILITY MODALITY, HEMATOCRIT, AND UREA REDUCTION RATIO, 2003-2006	17
<i>Modality (5a, 5b)</i>	17
<i>Hematocrit (5c-5i)</i>	17
<i>Urea Reduction Ratio (5j-5n)</i>	18
IX. VASCULAR ACCESS INFORMATION (CMS FISTULA FIRST), 2004-2006	19
<i>Prevalent hemodialysis patient months (6a)</i>	19
<i>Vascular access type in use (6b)</i>	19
<i>Arteriovenous Fistulae placed (AV) (6c)</i>	19
<i>Catheter only \geq 90 days (6d)</i>	19
<i>Incident hemodialysis patients (6e)</i>	20
<i>Vascular access type in use (6f)</i>	20
<i>Arteriovenous Fistulae placed (AV) (6g)</i>	20
X. CHARACTERISTICS OF NEW DIALYSIS PATIENTS, 2003-2006 (FORM CMS-2728)	20
<i>Patient Characteristics (7a-7m)</i>	21
<i>Average Lab Values Prior to Dialysis (7n-7q)</i>	21
<i>Nephrologist Care Prior to Start of ESRD Therapy (7r-7s)</i>	21
<i>Kidney Transplant Options (7t-7v)</i>	21
<i>Comorbid Conditions (7w-7x)</i>	21
XI. SUMMARIES FOR ALL DIALYSIS PATIENTS TREATED AS OF DECEMBER 31 OF EACH YEAR, 2003-2006	21
<i>Patients Treated on 12/31 of Year (8a)</i>	22
<i>Age (8b, 8c)</i>	22
<i>Female (8d)</i>	22
<i>Race (8e)</i>	22
<i>Ethnicity (8f)</i>	22
<i>Cause of ESRD (8g)</i>	22
<i>Duration of ESRD (8h, 8i)</i>	22
<i>Nursing facility patients (8j)</i>	22

<i>Modality (8k)</i>	23
XII. COMORBIDITIES REPORTED ON MEDICARE CLAIMS FOR MEDICARE DIALYSIS PATIENTS TREATED AS OF DECEMBER 31 OF EACH YEAR, 2003-2005	23
<i>Patients Treated on 12/31 of Year (9a)</i>	23
<i>Comorbid Conditions (9b)</i>	23
<i>Average Number of Comorbid Conditions (9c)</i>	23
XIII. HOW PATIENTS WERE ASSIGNED TO THIS FACILITY AND END OF YEAR PATIENT STATUS, 2003-2006	23
<i>Number of Patients Placed in Facility (10a)</i>	23
<i>Initial Patient Placement for the Year in This Facility (10b)</i>	23
<i>Patient Status at End of Year (10c)</i>	24
XIV. PATIENT AND STAFF COUNTS FROM ANNUAL FACILITY SURVEY (FORM CMS 2744), 2003-2006	24
<i>Patients Treated during the Year (11a-11d)</i>	24
<i>Patients Treated as of 12/31 (11e-11g)</i>	24
<i>Staffing (11h-11i)</i>	24
XV. SURVEY AND CERTIFICATION ACTIVITY, 2007	25
<i>Date and type of last survey (12a, 12b)</i>	25
<i>Compliance condition after last survey (12c)</i>	25
<i>Deficiencies cited at last survey (12d, 12e)</i>	25
XVI. FACILITY INFORMATION, 2007	25
XVII. PLEASE GIVE US YOUR COMMENTS	26
REFERENCES	27

I. Purpose of this Guide and the Dialysis Facility Reports

This guide explains in detail the contents of the Dialysis Facility Reports that were prepared for each dialysis facility under contract to the Centers for Medicare & Medicaid Services. Included here are the reports' objectives, discussions of methodological issues relevant to particular sections of each report (e.g., mortality, hospitalization, and transplantation) and descriptions of each data summary.

In the interest of stimulating quality improvement efforts and facilitating the quality improvement process, the Dialysis Facility Reports make information available to those of you involved in dialysis care and the assurance of its quality. This report allows you to compare the characteristics of your facility's patients, patterns of treatment, and patterns in transplantation, hospitalization, and mortality to local and national averages. Such comparisons help you to evaluate patient outcomes and to account for important differences in the patient mix — including age, sex, race, and patients' diabetic status — which in turn enhances each facility's understanding of the clinical experience relative to other facilities in the state, Network, and nation.

“What's New”

As part of a continuing effort to improve the quality and relevance of this report for your facility, the URR measure is now based on all Medicare patients with ESRD for 183+ days, rather than 365+ days.

Other major improvements to the 2007 DFR:

- The mortality summaries reported in Table 1 and used by DFC are now adjusted for the percent of patients assigned to the dialysis facility that are also identified as nursing home patients by the Nursing Home Minimum Data Set on December 31st of each year.
- Comorbid conditions as reported on dialysis claims are now summarized in the DFR on Table 9.
- Prior state survey deficiencies are now included in Table 12.

II. Overview

The University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) has produced the 2007 Dialysis Facility Reports with funding from the Centers for Medicare & Medicaid Services (CMS). The UM-KECC sends the reports to each ESRD Network Office, which in turn sends them to personnel at each dialysis facility. Your Facility Director may of course share these results with others. Those state agencies which are responsible for certifying dialysis facilities also receive the reports.

Each report provides summary data on each facility's dialysis patients for the years 2003-2006. We compiled these summaries using the UM-KECC ESRD patient database, which is largely derived from the CMS Program Medical Management and Information System (PMMIS/REMIS), the Standard Information Management System (SIMS) database maintained by the 18 ESRD Networks, the National Vascular Access Improvement

Initiative's Fistula First project, the CMS Annual Facility Survey (Form CMS-2744), Medicare dialysis and hospital payment records, the CMS Medical Evidence Form (Form CMS-2728), transplant data from the Organ Procurement and Transplant Network (OPTN), the Death Notification Form (Form CMS-2746), the Nursing Home Minimum Dataset, and the Social Security Death Master File. The database is comprehensive for Medicare patients. Non-Medicare patients are included in all sources except for the Medicare payment records. SIMS provides tracking by dialysis provider and treatment modality for non-Medicare patients.

This year we provided reports to the ESRD Networks for more than 5000 Medicare-approved dialysis facilities in the United States. We did not send reports to transplant-only facilities or Veterans Administration facilities. We have suppressed information about the Standardized Mortality Ratio (SMR) and its components for facilities with either less than one expected death for any given year, or fewer than three expected deaths for the four-year period. Statistics produced for such a small group of patients can be unstable and particularly subject to random variation, and thus difficult to interpret. Similarly, we suppressed information about the Standardized Total Admission Ratio (STAR) and its components, as well as the Standardized Transplantation Ratio and its components, for facilities with either less than one expected event (hospitalization or transplant) for any given year, or fewer than three expected events for the three- or four-year period.

This is the twelfth in this series of individualized reports. We welcome your participation and feedback concerning the clarity, utility, limitations, and accuracy of this report. You will find information on how to directly provide feedback to us at the UM-KECC in Section XVII.

This guide discusses the meaning of the data summaries each report provides, and describes the methodology used to calculate each summary (Sections III-XVI). Sections III-XVI are organized according to the order of the summaries in the Dialysis Facility Report, and may serve as references for their interpretation. Since in many cases, understanding a particular section's contents requires you to understand the issues presented in the previous section, we recommend that you review Sections III-XVI in order.

The report starts with five pages of text highlights for your facility, followed by thirteen tables each with detailed information for your facility. To provide more stable estimates of patient outcomes, we combined mortality information (Table 1) over a four-year period, 2003-2006. Similarly, we combined hospitalization information (Table 2) over a three-year period, 2003-2005, and transplant information (Table 3) over a four-year period, 2003-2006. The separate estimates provided for each year allow you to evaluate time trends. Note that for the three- and four-year summaries, individual patients typically contribute data for more than one year. We document self-reported vascular access (Table 6) for 2004-2006. Comorbidities as they are reported on Medicare claims for 2003-2005, as well as regional averages for 2005 are reported in Table 9. Table 11 reports Annual Facility Survey information for 2003-2006. Table 12 reports information about the last survey at this facility as well as information about deficiencies cited at the

last state survey. Table 13 reports general information about your facility as of June 2007. The remaining tables (4, 5, 7, 8, and 10) report patient characteristics and practice patterns for your facility each year from 2003-2006, as well as regional averages for 2006 for comparison.

Each row of a table in the report summarizes an item. Your facility has a column for each time period, and in most cases, three columns for the corresponding geographical summaries, including averages for your facility's state, its ESRD Network, and the entire nation. Whenever the statistic reported was a count (*n*), we calculated regional and national averages by taking the average count for all facilities in that area. When the statistic reported for a period included more than one year, we annualized regional and national values to make them comparable to a single-year period. When a statistic was a percent, rate, or ratio, we calculated regional and national summaries by pooling together all individual patients in that area to obtain an estimate for that area as if it were one large facility. We do not report state summary data for dialysis facilities in states or U.S. territories with only one or two dialysis units, with the exception of Annual Facility Survey data, which is public information. We do provide summaries for the geographic aggregate of the ESRD Network and the nation for facilities in these states or territories.

III. Assigning Patients to Facilities

This section describes the methods we used to assign patients to a facility in order to calculate the summaries appearing in Tables 1-3 and 8-10. The sections on the other tables describe the other tables' methods for identifying patients.

Because some patients receive dialysis treatment at more than one facility in a given year, we use standard methods based on assigning person-years to a facility, rather than on assigning a patient's entire follow-up to a facility. We developed conventions which define the group of patients assigned to a facility at any time during the particular year. This method is described below.

General Inclusion Criteria for Dialysis Patients

A patient's follow-up in the database can be incomplete during the first 90 days of ESRD therapy. For the purposes of this report, we only entered a patient's follow-up into the tabulations after that patient had received chronic renal replacement therapy for at least 90 days. This minimum 90-day period assures that most patients are eligible for Medicare insurance either as their primary or secondary insurer. It also excludes from analysis patients who died during the first 90 days of ESRD, since such patients have incomplete data.

In order to exclude patients who only received temporary dialysis therapy, we assigned patients to a facility only after they had been on dialysis there for at least 60 days. This 60 day period is used both for patients starting renal replacement therapy for the first time and for those who returned to dialysis after a transplant. That is, deaths and survival during the first 60 days do not impact the SMR of that facility.

Identifying Patients Treated at Each Facility (see also Section XIII)

For each patient, we identified the dialysis provider at each point in time using a combination of Medicare-paid dialysis claims, the Medical Evidence Form (Form CMS-2728), and data from the Standard Information Management System (SIMS). Starting with day 91 of ESRD, we determined facility treatment histories for each patient, and then listed each patient with a facility only once the patient had been treated there for 60 days. When a patient transferred from a facility, the patient remained assigned to it in the database for 60 days. This continued tabulation of the time at risk for 60 days after transfer from a facility attributes to a facility the sequelae of treatment there, even when a patient was transferred to another facility (such as a hospital-based facility) after his or her condition worsened.

In particular, we placed patients in their initial facility on day 91 of ESRD once that facility had treated them for at least 60 days. If on day 91 a facility had treated a patient for fewer than 60 days, we waited until the patient reached day 60 of treatment at that facility before placing him or her there. State and Network summaries do not include patients who were not assigned to a facility; these patients are, however, included in the U.S. summaries.

Using paid dialysis claims and SIMS data to determine whether a patient has transferred to another facility, we attributed patient outcomes to the patient's original facility for 60 days after transfer out. On day 61 after transfer from a facility, we placed the patient in the new facility once the patient had been treated at the new facility for 60 days. When a patient was not treated in a single facility for a span of 60 days (for instance, if there were two switches within 60 days of each other), we did not attribute that patient to any facility.

Patients were removed from facilities upon receiving transplants. Patients who withdrew from dialysis or recovered renal function remained assigned to their treatment facility for 60 days after withdrawal or recovery.

We removed any patient from a facility's analysis whose last evidence of dialysis treatment at that facility was one year old, considering them lost to follow-up. In other words, if a period of one year passed with neither paid dialysis claims nor SIMS information to indicate that a patient was receiving dialysis treatment, we considered the patient lost to follow-up, and did not continue that patient in the analysis. When dialysis claims or other evidence of dialysis reappeared, the patient was entered into analysis after 60 days of continuous therapy at a single facility.

Table 10 reports how we assigned patients to your facility. It also displays their status at year's end (see Section XIII).

IV. Mortality Summary for All Dialysis Patients, 2003-2006

This report compares patient outcomes in your facility with national averages. Table 1 provides information about patient mortality. We have calculated a relative mortality rate, or Standardized Mortality Ratio (SMR), for patients in your facility. The SMR compares the observed death rate in your facility to the death rate that was expected

based on national death rates for patients with the same characteristics as those in your facility (Wolfe, 1992). The SMR uses expected mortality calculated from a Cox model (SAS Institute Inc., 2000; Andersen, 1993; Collett, 1994), adjusting for patient age, race, ethnicity, sex, diabetes, duration of ESRD, nursing home status, patient comorbidities at incidence, body mass index (BMI) at incidence, and population death rates.

The SMR accounts for many patient characteristics known to be associated with mortality, but cannot account for all factors that may explain differences in mortality between facilities. For example, since the SMR accounts for age and diabetes, an older average age or large percentage of diabetic patients at a facility would not elevate the SMR. Other factors, such as nutritional status, factors relating to the process of care, or comorbid conditions that developed after incidence, are not accounted for. **Therefore, if the SMR statistic indicates potential differences in mortality for your facility compared to regional or national averages, please consider the role other important factors play within your facility.** As with the hospitalization and transplantation summaries which are described below in Sections V and VI, you will find the mortality summaries most informative if you use them as part of an integrated quality assurance process.

We reported information on the mortality of dialysis patients for each year between 2003 and 2006, and also summarized the statistic for the 2003-2006 period. We also reported the averages in your state, your ESRD Network, and the nation for this combined four-year period.

Patients (1a)

We based the mortality summaries on the dialysis patients who received treatment in your facility according to the conventions described in Section III. Patients who died of AIDS are no longer excluded from this count, because starting in 2005, AIDS is not listed as a cause of death on the ESRD Death Notification Form (Form 2746) and therefore, we can no longer identify patients who died of AIDS.

Patient Years at Risk (1b)

For all patients, time at risk began at the start of the facility treatment period (see Section III) and continued until the earliest occurrence of the following: transplant; date of death; end of facility treatment period; or December 31 of the year. A patient may have been treated at one facility for multiple periods during the same year; patient years at risk include time at risk for all periods of treatment at a facility.

Deaths (1c)

We reported the number of deaths that occurred among dialysis patients during each year, as well as the total across the years. This count does not include deaths from street drugs or accidents unrelated to treatment. Deaths from these causes varied by facility, with certain facilities (in particular, urban facilities that treated large numbers of male and young patients) reporting large numbers of deaths from these causes and others reporting extremely low numbers (Turenne, 1996). Since these deaths are unlikely to have been due to treatment facility characteristics, we excluded them from the calculations. This

count also does not include deaths related to Hurricanes Katrina and Rita. These are identified as deaths occurring between August 27, 2005 and October 31, 2005 that are noted in the Death Notification Form or in SIMS as being related to Hurricane Katrina or Hurricane Rita.

Expected Deaths (1d)

We calculated the expected deaths as $-ln(S_i(t_i))$, where $S_i(t)$ was the survival curve from a Cox model adjusted to the characteristics of patient i and t_i was the amount of follow-up time (patient years at risk) for that patient during the year (SAS Institute Inc., 2000; Andersen, 1993; Collett, 1994). We adjusted the Cox model for age, race, ethnicity, sex, diabetes, years since start of ESRD, nursing home status, patient comorbidities at incidence, and patient BMI at incidence (BMI = weight (kg)/ height² (m²)). In cases where the comorbidities or BMI were missing for a patient, we used the average values of the group of patients with similar characteristics (age, race, ethnicity, sex, diabetes). We also controlled for age-adjusted population death rates by state and race, based on the U.S. population in 2002-2004 (National Center for Health Statistics, 2006). As with the deaths in 1c, we then summed these expected deaths in order to obtain the total number of deaths expected for each year at your facility, and we summed the annual values to yield the expected number of deaths over the four-year period for each facility.

Death Rate per 100 Patient Years (1e)

We calculated the death rate by dividing the number of deaths by the total number of patient years at risk and then multiplying the result by 100. This yielded a measure of your facility's death rate during the period. We expressed the number of deaths relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Expected Death Rate per 100 Patient Years (1f)

We obtained the expected death fraction by dividing the number of expected deaths by the number of patient years at risk, and then multiplying the result by 100. This measures your facility's expected death rate based on the age, race, ethnicity, sex, diabetes, years since start of ESRD, nursing home status, comorbidities at incidence, BMI at incidence, and population death rates. We expressed the expected number of deaths relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Categories of Death (1g, 1h, 1i)

Row 1g reports the percentage of dialysis patient deaths (row 1c) for which the CMS ESRD Death Notification Form (Form-2746) indicated that the patient voluntarily discontinued renal replacement therapy prior to death. For the causes of death calculations in rows 1h and 1i, we considered all causes of death (primary and secondary) provided on the form. Row 1h reports the percentage of deaths in 1c listed as due to infection for either the primary or one of the secondary causes of death.

Line 1i reports the number of patients who, according to any of the primary or secondary causes of death listed on the Death Notification Form, died from accidents unrelated to

dialysis treatment, died from street drugs, or those whose deaths were determined to be related to Hurricanes Katrina or Rita (see 1c). We did not include these dialysis-unrelated deaths in the total death count in line 1c or the SMR; therefore, differences in SMRs between different dialysis facilities do not correspond to differences in the number of dialysis-unrelated deaths.

Information on category of death may help you interpret the SMR value for your facility. For example, a high rate of withdrawal will not increase the SMR substantially if the patients who withdraw have a short expected lifetime, though it will cause an increase if patients have a long expected remaining life. However, we would advise using caution when interpreting these percentages by category of death, since we did not adjust them for patient characteristics. Expressing this information as a simple percentage of the total number of deaths does not indicate whether the percentage of deaths in any particular category differs from the national average for similar patients.

Standardized Mortality Ratio (SMR) (1j)

The SMR equals the ratio of the actual number of deaths (1c) divided by the expected number of deaths (1d). The SMR estimates the relative death rate ratio for your facility, as compared to the national death rate. Qualitatively, the degree to which your facility's SMR varies from 1.00 is the degree to which it exceeds (>1.00) or is under (<1.00) the 2003-2006 national death rates for patients with the same characteristics as those in your facility.

As stated previously, we adjusted the SMR for age, race, ethnicity, sex, diabetes, duration of ESRD, nursing home status, comorbidities at incidence, BMI at incidence, and population death rates. The SMR indicates whether patients treated in your facility had higher or lower mortality than expected when adjusted for age, race, ethnicity, sex, diabetes, years of ESRD, nursing home status, comorbidities, BMI, and population death rates.

Detailed statistical methodology for the SMR is included in a separate document titled *Technical Notes on the Standardized Mortality Ratio for the Dialysis Facility Reports*. This document and an accompanying Microsoft Excel spreadsheet are available on the UM-KECC website: <http://www.sph.umich.edu/kecc/usr/usr.htm>

Quantitatively, if your facility's death rates equal the national death rates (in deaths per patient year or per year at risk) times a multiplicative constant, then the SMR estimates that multiplicative constant. If the multiplicative constant varies for different subgroups of patients, then the SMR estimates a weighted average of those constants according to your facility's patient mix. For example, an SMR=1.10 would indicate that your facility's death rates typically exceed national death rates by 10% (e.g., 22 deaths observed where 20 were expected, according to your facility's patient mix). Similarly, an SMR=0.95 would indicate that your facility's death rates are typically 5% below the national death rates (e.g., 19 versus 20 deaths). An SMR=1.00 would indicate that your facility's death rates equal the national death rates.

We calculated the regional and national summaries as the ratio of the total number of observed deaths among patients from each region to the number of expected deaths among patients from each region (1c/1d).

Why the national SMR may not be exactly equal to 1.00

The reported 2003-2006 SMR for the U.S. as a whole may not be precisely equal to 1.00. The SMR value for the U.S. given in the Dialysis Facility Reports does not include all U.S. dialysis facilities in its calculation. In particular, as discussed in the Overview, transplant-only, Veteran's Administration, and non-Medicare facilities are not included in the geographic summaries.

Random variation

The SMR estimates the true ratio of death rates at your facility relative to the national death rates. An SMR value that differs from 1.00 indicates that your facility's death rates differ from the national death rates. *However, the SMR's value varies from year to year above and below the true ratio, due to random variation.* Thus, your facility's SMR could differ from 1.00 due to random variation rather than to a fundamental difference between your facility's death rates and the nation's. Both the p-value and the confidence interval, discussed below, will help you interpret your facility's SMR in the face of such random fluctuations. We based our calculations of both items on an assumed Poisson distribution for the number of deaths at your facility.

P-value (1k)

The p-value measures the statistical significance (or evidence) for testing the one-sided hypothesis that the true ratio of death rates for your facility versus the nation is higher (or lower) than 1.00. The p-value is the probability that the SMR would, just by chance, deviate from 1.00 as much as does the observed SMR, and is sometimes naively interpreted as the probability that the true SMR equals 1.00. A smaller p-value tends to occur when the ratio differs more greatly from 1.00 and when one uses more patient data to calculate the SMR value. A p-value of less than 0.05 is usually taken as evidence that the ratio of death rates truly does differ from 1.00.

For instance, a p-value of less than 0.05 would indicate that the difference between your facility's death rates and the nation's is unlikely to have arisen from random fluctuations alone. The smaller the p-value, the more *statistically significant* the difference between national and individual facility death rates is. A small p-value helps rule out the possibility that an SMR's variance from 1.00 could have arisen by chance. However, a small p-value does not indicate the degree of importance of the difference between your facility's death rates and the nation's.

The SMR's actual quantitative value reflects the clinical importance of the difference between your facility's and the nation's death rates. An SMR that differs greatly from 1.00 is more important than an SMR in the range of 0.95 to 1.05.

Confidence Interval for SMR (II)

The 90% confidence interval gives a range of plausible values for the true ratio of facility-to-national death rates, in light of the observed SMR. The true ratio is less than the upper limit of the confidence interval 95% of the time and greater than the lower limit 95% of the time. The two limits enclose the true ratio between them 90% of the time.

Recommended Course of Action if SMR Is Elevated

In past years, Medical Directors have asked the UM-KECC what they should do if their SMR is elevated. Our general guidelines, which are not intended to be exhaustive, follow.

- 1) Does the SMR deviate from 1.00 by chance? If your facility has few patients, then random variation may explain the deviation. Evaluate the confidence interval and the p-value. Most likely, the true SMR lies between the confidence limits. If the p-value exceeds 0.05, or if the confidence interval includes 1.00 (crosses the 1.00 line), the SMR is not statistically significant at the 0.05 level, and random variation could plausibly explain its elevation. Please note that the p-value is based on an exact calculation, while the confidence interval is an approximation, accurate in most cases. In rare cases, these measures of statistical significance may differ, with one indicating a statistically significant result and the other an insignificant one. Should this occur, use the p-value rather than the confidence interval.
- 2) Is the result consistent across the years? See if the values are consistent from year to year or if there is a consistent trend towards higher or lower values. If not, then the results may be less reliable than if the individual year estimates follow a pattern.
- 3) Examine input data. Table 10 gives some details about the patients assigned to your facility. Your Network can provide you with a list of patients used in this report, which includes patient identifiers and death dates, if applicable. Consider whether the counts of patients by year are plausible over time, as well as for any one year. If this list contains substantial errors, we would like to know about them.
- 4) Consider other characteristics of your facility not adjusted for in the SMR. The SMR adjusts for age, race, ethnicity, sex, diabetes, years of ESRD, nursing home status, comorbidities, BMI, and population death rates. The SMR could differ from 1.00 because patients differ with respect to other important factors not adjusted for (e.g., poor nutritional status).
- 5) A statistically significant SMR greater than 1.10 likely reflects truly elevated mortality. Therefore, you may best address such a finding by evaluating various treatment factors in your unit, as well as other patient characteristics.

SMR Percentiles for This Facility (1m, 1n, 1o)

This section reports the percentile rank of your facility's SMR relative to all other facilities in the state, Network, and nation. This percentile — reported for each year's SMR and for the four-year combined SMR — is the percentage of facilities with an SMR

lower than your facility's. In other words, a high or low percentile indicates that your facility has a high or low SMR relative to other facilities in the state, Network, or nation.

V. Hospitalization Summary for Medicare Dialysis Patients, 2003-2005

Hospitalization rates strongly indicate patient morbidity and quality of life. The typical dialysis patient is admitted to the hospital once or twice a year. Hospitalizations – also very costly – represent approximately 37 percent of total Medicare expenditures for dialysis patients (U.S. Renal Data System, 2006). Measures of the frequency of hospitalization and diagnoses present at hospitalization help efforts to control escalating medical costs, and play an important role in providing cost-effective health care. Hospitalization summaries for Medicare dialysis patients are reported in Table 2.

This report includes summaries of the hospitalization rates among dialysis patients in your facility, along with comparative regional and national data. However, the reasons for differences in hospitalization rates by facility are complex. In some cases, a hospitalization may result from deteriorated patient health caused, for example, by inadequate dialysis. In other cases, a hospitalization to treat a pre-existing comorbid condition may effectively prevent additional or more serious hospitalizations. ***Thus, we provide hospitalization summaries in this report as indicators of the process of care, rather than as measures of patient outcomes in a facility.***

Hospitalization rates are more difficult to summarize than are mortality rates. First, a patient can be hospitalized more than once during a year. Further, hospitalization data are not always as complete as mortality data. Ideally, these tables include only patients whose Medicare billing records include all hospitalizations. To achieve this goal, we require that patients reach a certain level of Medicare-paid dialysis bills to be included in hospitalization statistics, or that patients have Medicare-paid inpatient claims during the period. We intend for this criterion to assure completeness of information on hospitalizations for all patients included in the years at risk. Dialysis patient provider periods include those months meeting the criterion of being within two months after the end of a month having at least \$900 of Medicare-paid dialysis claims or at least one Medicare-paid inpatient claim.

The *total admission rate* reports the total number of hospital admissions per year, including multiple admissions per patient. We treat adjacent hospitalizations or those separated by only one day as one hospital admission. We are unable to distinguish a hospital admission as an independent event from a re-admission that occurs largely as the consequence of a previous hospitalization. However, the frequency of all hospital admissions among patients in a facility may usefully measure the morbidity of dialysis patients. Summaries of the total number of hospital admissions are reported in Rows 2c through 2h. We calculated for each facility a Standardized Total Admission Ratio (STAR). Like the SMR, the STAR is based on comparing your facility's observed admission rate to the expected, national admission rates for 2003-2005 for patients with the same characteristics as those in your facility. We adjusted the STAR for age, race, sex, and diabetes.

We reported the hospitalization summaries for each year from 2003-2005 and for the entire three-year period. We reported the result for the average facility over the combined 2003-2005 period for regional and national summaries.

Medicare Dialysis Patients (2a)

The number of Medicare dialysis patients included in the hospitalization summaries (2a) is generally smaller than the number of patients included in the mortality summaries (1a). We calculated hospitalization rates based only on periods in which dialysis patients had satisfied the Medicare payment criterion (described above).

Patient Years at Risk (2b)

The number of patient years at risk indicates the total amount of time we followed patients in this table's analyses. For all patients, time at risk began at the start of the facility treatment period (see Section III) and continued until the earliest occurrence of the following: three days prior to a transplant; date of death; end of facility treatment; or December 31 of the year. Since a facility may have treated a patient for multiple periods during the same year, patient years at risk includes time at risk for all periods of treatment at your facility.

Patient Years at Risk for Total Admissions (2c)

We used the number of patient years at risk for total admissions to calculate the expected total admission rate. For calculating *expected total admissions*, time at risk equaled the patient years at risk (2b) minus any time spent in the hospital. Thus, the number of patient years at risk for total admissions included all time not spent in the hospital during that year, since a patient could not be at risk for an admission while still in the hospital. As before, the time-at-risk period continued until the earliest of either death, end of the facility treatment period, or December 31. Since a facility may have treated a patient for multiple periods during the same year, patient years at risk includes time at risk while not in the hospital for all periods of treatment at your facility.

Total Admissions (2d)

This represents the total number of hospital admissions among the Medicare dialysis patients eligible for the hospitalization summaries. The total number of admissions includes multiple admissions (i.e., second hospitalization for the same patient, third, etc.).

The number of admissions in a particular calendar year includes a hospital admission in which a patient was admitted during one year but was discharged the following year (e.g., a stay from December 31-January 1). Such admissions are not counted again for the following year.

Expected Total Admissions (2e)

We calculated the expected number of hospital admissions among Medicare dialysis patients in a facility for 2003-2005 based on national hospital admission rates (admissions per year) by age, sex, race, and diabetes. Multiplying the time at risk for each patient in a facility by the national admission rate (total admissions per year) for the

corresponding age-diagnosis-sex-race patient subgroup yielded an expected number of admissions for each patient. Row 2e reports your facility's sum of expected total admissions.

Observed Admission Rate per 100 Patient Years (2f)

We calculated the admission rate by dividing the number of admissions by the total number of patient years at risk and then multiplying the result by 100. This yielded a measure of your facility's admission rate during the period. We expressed the number of admissions relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Expected Admission Rate per 100 Patient Years (2g)

We obtained the expected admission fraction by dividing the number of expected admissions by the number of patient years at risk, and then multiplying the result by 100. We expressed the expected number of admissions relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Standardized Total Admission Ratio (2h)

We calculated the standardized ratio for total admissions (STAR) by dividing the observed total admissions by the expected total admissions. As with the SMR, it enables a comparison of your facility's experience to the national average. A STAR of less than 1.00 indicates that your facility's total number of admissions was less than expected, based on national rates; whereas a STAR of greater than 1.00 indicates that your facility had a rate of total admissions higher than the national average. We adjusted this measure for your facility's patient age, race, sex, and diabetes characteristics.

Diagnoses Present at Admission (2i, 2j)

Row 2i reports the percentage of patients in 2a who had septicemia reported as one of the diagnoses on a hospital bill with a start date during a period of treatment at your facility. In order to determine which hospitalizations listed septicemia as a contributing cause, we first identified ICD-9 diagnosis codes associated with septicemia, and then looked for these codes on the hospital bills (in any position on the list of diagnoses). Similarly, row 2j gives the percentage of patients who had acute myocardial infarction reported as one of the diagnoses on a hospital bill with a start date during a period of treatment at your facility. We also identified these through their ICD-9 diagnosis codes. A patient may have had a septicemia or myocardial infarction hospitalization during the year even if the patient was not counted as being admitted during the year, because total admissions (2d) do not include hospitalizations that started in one year and continued into the next. Rows 2i and 2j include all bills, even if the patient did not leave the hospital in between bills. Note that a patient may appear in both the septicemia and myocardial infarction counts.

Average Length of Stay (2k)

We reported, as a measure of the severity of hospitalizations, the average duration (in days) of hospital admissions among Medicare dialysis patients eligible for the

hospitalization summaries. We calculated this duration from Medicare payment records, which listed an admission and discharge date for each hospitalization. We calculated the average duration per admission, with no adjustment for patient characteristics.

One Day Admissions (2l)

We reported the percentage of total hospital admissions lasting one day or less — a value based on the total number of admissions reported in row 2d. One-day admissions included hospitalizations in which the patient was discharged either the same or the following day. We did not adjust this statistic for patient characteristics.

Average Days in the Hospital per Dialysis Patient Year (2m)

This value represents the average number of days spent in the hospital per year for patients in your facility. This measure of hospital use reflects both the number and length of hospital admissions. We calculated this summary as the ratio of the total number of hospital days divided by the total number of patient years at risk (2b).

Number of hospital days includes days until discharge for all admissions that start sometime between the patient's start date and the end of the year. Thus, if a patient who was admitted near the end of one year was not discharged until the following calendar year (e.g., admitted on 12/28/2003 and discharged on 1/4/2004), the number of hospital days included those spent in the hospital during the subsequent year (four days during 2003 plus four days during 2004 = eight days in hospital).

We used the number of patient years at risk reported in 2b as the denominator in the calculation of the number of hospital days per patient year. Patients were at risk for spending another day in the hospital whether or not they were hospitalized at the time. We expressed the number of hospital days as relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year. We made no adjustments for patient characteristics in this statistic.

VI. Transplantation Summary for Dialysis Patients under Age 70 who have not Previously Received a Transplant, 2003-2006

The results of numerous studies have indicated that the recipients of renal transplants have better survival than comparable dialysis patients (Wolfe, 1999). Although the number of renal transplants has increased, it has not kept pace with the rising number of patients on transplant waiting lists. This report includes Standardized Transplantation Rates (STRs) for dialysis patients. We calculated the STR using the same methods as the SMR, described in more detail in Section IV. Adjustments for the STR differed from those for the SMR because the STR was adjusted for age only. Since we included patients in this table only once they reached day 91 of ESRD, we excluded patients who received a pre-emptive transplant or a transplant within the first three months of treatment. You will find these statistics useful in that they allow a facility to compare the rate of transplantation for the dialysis patients they treat, though these statistics should not be interpreted as including all transplants. Footnote 3 gives the percentage of transplants in the U.S. that were not included because the transplant occurred less than 90

days after the start of ESRD, as well as those that were not included because the patients were not assigned to facilities at times of transplant.

Eligible Patients (3a)

The number of dialysis patients included in this report's transplantation summaries (3a) was typically much smaller than the number of patients included in the mortality summaries (1a) for two reasons. First, all transplantation statistics in this report refer only to those patients under 70 years of age because transplants in people aged 70 or greater occurred much less frequently than did transplants in younger patients. Second, we computed transplantation statistics only for patients who had never received a kidney transplant before.

Patient Years at Risk (3b)

We limited our calculations for 3b to patients under the age of 70 who had not previously received a transplant. For all patients, time at risk began at the start of the facility treatment period (see Section III) and continued until the earliest of the following occurrences: transplant; date of death; end of the facility treatment period; or December 31. A patient may have been treated at one facility for multiple periods during the same year; in such a case, the number of patient years at risk included time at risk for all periods of treatment at that facility.

Actual First Transplants (3c)

Row 3c reports the number of dialysis patients under the age of 70 in each facility who received a first transplant.

Expected First Transplants (3d)

We calculated the expected number of patients who had received transplants during the year in a manner similar to calculating the expected number of deaths, but with one important difference: We adjusted transplantation statistics for age only.

We did not adjust transplantation statistics for sex, race, or diabetes because, generally speaking, these are inappropriate adjustments for access to transplantation. We calculated the expected number of first transplants during the year for each patient as $-\ln(S_i(t_i))$, where $S_i(t)$ is the survival curve from a Cox model adjusted to the age of patient i and t_i is the amount of follow-up time (patient years at risk) for that patient during the year (SAS Institute Inc., 1999; Andersen, 1993; Collett, 1994). Table 3 sums and reports the total number of patients expected to receive a first transplant from your facility, with corresponding regional and national averages.

First Transplant Rate per 100 Patient Years (3e)

We calculated the first transplantation rate for patients under 70 by dividing the number of patients receiving a kidney transplant for the first time during the period (3c) by the total number of patient years at risk for transplant (3b), and then multiplying the result by 100. We expressed the number of transplants relative to the total number of patient years

(rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Expected First Transplant Rate per 100 Patient Years at Risk (3f)

We calculated the expected first transplantation rate by dividing the expected number of first transplants (3d) by the total number of patient years at risk (3b), and then multiplying the result by 100. We expressed the expected number of transplants as relative to the total number of patient years (rather than the number of patients) because many patients did not receive treatment for a full calendar year.

Number of Deceased Donor Transplants (3g)

Row 3g reports by year the number of patients who received transplants from a deceased donor. This is the number of transplants from row 3c that were from a deceased donor.

Standardized Transplantation Ratio (3h)

The Standardized Transplantation Ratio (STR) is the ratio of the observed number of first transplants to the expected number of first transplants for your facility, given the age composition of your facility's patients. Note that we adjusted the STR for patient age only. Interpret the STR as you would the SMR. An STR of 1.00 indicates that the observed number of transplants in your facility equals the estimated national rate, adjusted for age. An STR of less than 1.00 indicates that your facility's transplant rate is lower than the national average. An STR greater than 1.00 indicates that your facility's transplant rate exceeds the national average. The amount by which an STR lies above or below 1.00 corresponds to the percentage your facility's transplant rate is above or below the national average, respectively. For example, an STR of 0.90 would mean that your facility's rate of transplantation is 10% less than the estimated national rate (e.g., nine transplants where ten are expected). An STR exceeding 1.00 is desirable.

We calculated the STRs for the regional and national summaries as the ratio of the total observed number of first transplant summed across facilities to the total expected number of first transplants summed across facilities.

Random Variation

The STR tends to show more random variation than the SMR because numbers of transplants are much smaller than numbers of deaths. Small numbers of events contribute to instability, increasing the chances that an observed result owes to chance rather than to the true ratio of observed-to-expected transplants. This makes p-values and confidence intervals instrumental in interpreting your facility's STR. We calculated these statistics based on an assumed Poisson distribution of the observed number of patients transplanted.

P-value (3i)

The p-value measures the statistical significance (or evidence) for testing the one-sided hypothesis that the true ratio of transplantation rates for your facility versus the nation is higher (or lower) than 1.00. We used the p-value to determine the statistical significance of the STR. The p-value indicates the probability that the result obtained owed to chance

alone. A low p-value means that chances are low that the STR differs from the national average merely because of random variation. A p-value of less than 0.05 usually indicates a result's statistical significance. You should also use the absolute magnitude of the STR's deviation from 1.00 to determine its clinical importance.

Confidence Intervals for STR (3j)

We also present 90% confidence intervals as a further check of statistical significance. These two limits enclose the true ratio between them approximately 90% of the time. Statistically significant confidence intervals do not contain 1.00.

STR Percentile for This Facility (3k, 3l, 3m)

This section reports the percentile rank of your facility's STR relative to all other facilities in the state, Network, and nation. We report these percentiles for each year's STR and for the four-year combined STR. The percentile indicates the percentage of facilities with an STR **lower** than your facility's STR. In other words, a high or low percentile number indicates that your facility has a high or low STR relative to other facilities in the state, Network, or nation.

VII. Waitlist Summary for Dialysis Patients under Age 70 Treated as of December 31 of Each Year, 2003-2006

The results of numerous studies have indicated that the recipients of renal transplants have better survival than comparable dialysis patients (Wolfe, 1999). The first step in the transplant process is getting placed on the transplant waitlist.

Eligible Patients on 12/31 (4a)

This table reports waitlist summary statistics for all dialysis patients under age 70 being treated on December 31 of each year at your facility. Row 4a reports the number of dialysis patients included in the waitlist summaries. All waitlist statistics in this profile refer only to those patients less than 70 years of age because transplants in people aged 70 or greater occur with much less frequency than do transplants in younger patients. This table gives a snapshot of the waitlist at four dates. The criteria for including patients in this table are different than those described in Section III for Tables 1, 2, and 3. For this table, we included patients at the facility they were in on December 31 of each year according to claims data or SIMS. The 60-day transfer rule did not apply, and we included patients new to dialysis (the 90 day rule did not apply).

Patients on the Waitlist (4b)

Row 4b reports the percentage of patients in 4a who were on the kidney or kidney-pancreas transplant waitlist as of December 31, with the corresponding national percentage for 2006 reported for comparison.

P-value (4c)

We used a one-sided p-value to test the hypothesis that the true percentage of patients on the waitlist reported in row 4b is higher (or lower) than the U.S. value for that year.

Footnote 3 shows the percentage of patients on the waitlist in the U.S. for each year used in this comparison. The p-value indicates the probability that the difference between the percentage of patients on the waitlist in your facility and in the U.S. occurred due to chance. A low p-value means that the chances are low that the facility percentage was higher or lower than the national average merely because of random variation. A p-value of less than 0.05 usually indicates a result's statistical significance. You should also use the absolute magnitude of the difference between your facility and national percentage of patients on the waitlist to determine its clinical importance.

Patient Characteristics (4d-4e)

Lines 4d and 4e break down the information in lines 4a and 4b by various patient characteristics. Line 4e reports the patient counts by age, sex, race and ethnicity, cause of ESRD, previous transplant, and years of ESRD treatment. These counts sum to line 4a for each set of categories. Line 4d reports the percentage of patients in each category in 4e who were on the kidney or kidney-pancreas transplant waitlist. State, Network, and U.S. averages for 2006 are given for comparison.

VIII. Facility Modality, Hematocrit, and Urea Reduction Ratio, 2003-2006

Table 5 reports information on facility practice patterns, each section of which includes a slightly different group of patients. We restricted dialytic modality and hematocrit information to patients who have had ESRD for at least 90 days. Information on urea reduction ratio is restricted to patients who have had ESRD for at least 183 days. The inclusion criteria are described in more detail below. Table 5 includes state, Network, and U.S. summaries for 2006 only.

Modality (5a, 5b)

We based the reported dialytic modality information on all Medicare dialysis claims submitted by your facility, excluding patient claims that started before day 90 of ESRD. Each patient treated during January 2003 through December 2006 at your facility was classified as receiving hemodialysis (including home hemodialysis), CAPD/CCPD, or other dialysis. Patients were categorized as receiving 'other dialysis' if they had claims for both hemodialysis and peritoneal dialysis in the same year. Rows 5a and 5b report the number and percentage of patients who received each of these therapeutic modalities.

Hematocrit (5c-5i)

We based the hematocrit information reported in lines 5c to 5i on all Medicare dialysis claims submitted by your facility that indicated the use of an erythropoiesis stimulating agent (ESA), specifically, the use of epoetin alfa or darbepoetin alfa. We calculated hematocrit as three times hemoglobin for claims that report hemoglobin but not hematocrit. We included neither patient claims starting before day 90 of ESRD nor claims with hematocrit values less than 14 or greater than 60. Line 5c reports the number of patients for whom at least four claims fulfilling these criteria were submitted by your facility for each year. A patient treated at more than one facility during the year was

included in the report for each facility (as long as the patient had at least 4 claims from the facility). For each patient in line 5c, we calculated the average hematocrit reported on claims submitted by your facility.

We summed the average hematocrit values for the patients in 5c and then divided by the number of patients in 5c in order to obtain your facility average reported in 5d. Row 5e presents the percentage of patients from 5c in each of four hematocrit categories. The KDOQI guidelines recommend that all patients have minimum hemoglobin of 11 which corresponds to a hematocrit value of 33 (NKF-KDOQI, 1997; NKF-KDOQI, 2001; NKF-KDOQI, 2006) Line 5f reports the percentage of patients in row 5c whose average hematocrit was 33 or greater. This information is reported separately for hemodialysis and peritoneal dialysis patients in line 5i.

We report in line 5g the upper and lower limits of the 90% confidence intervals for the percentage of patients whose average hematocrit was 33 or greater for each year.

Line 5h reports for each year the percentile rank of your facility's hematocrit (percentage of patients who meet KDOQI guidelines for hematocrit) relative to all other facilities in the state, Network, and nation.

In line 5i, the percent of patients whose average hematocrit is 33 or greater was reported separately for hemodialysis (HD) and peritoneal dialysis (PD) patients. For this statistic, claims from the facility for each patient were further divided by the treatment modality for the claim. This means that patients who received both HD and PD treatment at the facility appear in line 5i in both the HD and PD statistic. Patients who had at least 4 total claims from the facility appear in this line, even when there were fewer than 4 claims for the particular modality.

Urea Reduction Ratio (5j-5n)

We base the urea reduction ratio (URR) information reported in lines 5j-5n on all Medicare dialysis claims submitted by your facility, with the following two exclusions: claims which started before day 183 of ESRD for a patient; and claims with missing URR category. (Although we did not explicitly exclude peritoneal dialysis (PD) patients, PD patients would not have URR reported.) Line 5j reports the number of patients for whom at least four claims fulfilling these criteria had been submitted for your facility for each year. A patient who had been treated at more than one facility during the year was included at both facilities in line 5j when the patient had at least four claims with URR at each facility. We assigned each patient in 5j to whichever URR category had been most commonly reported during the year (ties went to the lower category). For patients treated at more than one facility during the year, we calculated separately the URR category for them for each facility based on the claims from each facility only.

Row 5k reports the percentage of patients in your facility in each category. The KDOQI guidelines recommend that all patients have a URR of 65% or more (NKF-KDOQI, 1997; NKF-KDOQI, 2001). Line 5l reports the percentage of patients in row 5j with URR that meets KDOQI guidelines (i.e., 65% or more).

We report in line 5m the upper and lower limits of the 90% confidence intervals for the percentage of patients whose URR was 65% or greater each year.

Line 5n reports the percentile rank of your facility's URR (percentage of patients who met KDOQI guides for URR) for each year, relative to all other facilities in the state, Network, and nation.

IX. Vascular Access Information (CMS Fistula First), 2004-2006

Table 6 reports vascular access data from the National Vascular Access Improvement Initiative's Fistula First project. The Fistula First project collects monthly data on vascular access from dialysis facilities. We summarized these data for each year, from 2004-2006, reporting yearly averages for each facility. We also report comparison values for 2006 for the state, Network, and U.S. These vascular access data are self-reported at the facility level.

Prevalent hemodialysis patient months (6a)

The Fistula First project defines the monthly prevalent hemodialysis patient count at a facility to include all non-transient patients (home and in-center) who receive hemodialysis as of the last day of that calendar month. Incident patients (those who received ESRD treatment for the first time ever) were included in this count. Line 6a reports the number of prevalent hemodialysis patient months reported at your facility each year. The number of patient months over a time period is the sum of patients reported for the months covered by the time period. An individual patient may contribute up to 12 patient months per year.

Vascular access type in use (6b)

Line 6b reports the type of vascular access in use during the last hemodialysis treatment of the calendar month, summarized for each year. This line reports the percentage of patient months in 6a in which the patient received dialysis through arteriovenous (AV) fistulae, AV grafts, catheters, or other access types for the last treatment of the month.

Patients who are reported as having an AV graft or a catheter in use with an AV fistula in place for *future* use are included in the AV graft or catheter category. For the Fistula First project, port access devices were reported as catheters. A patient's vascular access was classified as *Other* if it was considered to be different from the above categories (e.g., lifeline). Patients were classified as having missing access types if the vascular access data were missing from the record.

Arteriovenous Fistulae placed (AV) (6c)

Line 6c reports the average percentage of patient months in 6a in which an AV fistula was in place at the time of the last treatment of the month, regardless of whether or not the patient received hemodialysis treatment using this AV fistula.

Catheter only \geq 90 days (6d)

Line 6d reports the average percentage of patient months in 6a in which a catheter was in use at the last treatment of the month, a catheter was the *only* means of vascular access (i.e. patient did not have an AV fistula or AV graft in place), and the catheter was in

place for at least 90 days prior to treatment. For the Fistula First project, port access devices were reported as catheters.

Incident hemodialysis patients (6e)

Line 6e reports the total number of incident hemodialysis patients at your facility each year. The average number of incident patients during 2006 is reported for comparison for your state, Network, and the U.S. The Fistula First project defines incident hemodialysis patients to be non-transient hemodialysis patients (home and in-center) who received their first ever ESRD treatment during the month for which the data was reported. These patients are a subset of prevalent patients.

Vascular access type in use (6f)

Line 6f reports the type of vascular access in use during the last hemodialysis treatment of the calendar month in which the patient was incident, summarized for each year. This line reports the percentage of incident hemodialysis patients in 6e who received dialysis through arteriovenous (AV) fistulae, AV grafts, catheters, or other access types.

Patients who are reported as having an AV graft or a catheter in use with an AV fistula in place for *future* use are included in the AV graft or catheter category. For the Fistula First project, port access devices were reported as catheters. A patient's vascular access was classified as *Other* if it was considered to be different from the above categories (e.g., lifeline). Patients were classified as having missing access types if the vascular access data were missing from the record.

Arteriovenous Fistulae placed (AV) (6g)

Line 6g reports the percentage of incident patients in 6e with an AV fistula in place at the last treatment for the month the patient was incident. Patients with an AV fistula in place are included in this line regardless of whether or not they received their hemodialysis treatments using the fistula.

X. Characteristics of New Dialysis Patients, 2003-2006 (Form CMS-2728)

Table 7 presents detailed data from the ESRD Medical Evidence Form (Form CMS-2728) on the characteristics of new patients in your facility by year. State, Network and national averages for 2006 are also shown for comparison. The patients represented in this table were hemodialysis and peritoneal dialysis patients who **started dialysis** between January 1, 2003 and December 31, 2006. Please note that we placed the patients included here *not* according to the conventions described in Section III, but rather according to the provider number that appeared on their Medical Evidence Forms.

For each patient characteristic, we present the average value for your facility as well as state, Network, and U.S. averages. We excluded from the calculations values for individual patients which fell outside the ranges shown in brackets [] on this table because we considered them to be clinically implausible.

Lines 7j-7m and 7s-7v were added to the Form CMS-2728 in June 2005; we report data on the DFR only for 2006 when complete data were available for the year.

Patient Characteristics (7a-7m)

Line 7a of this table gives the total number of forms submitted by your facility for the year. Lines 7b-7m deal with your patients' demographic characteristics, including their age, sex, ethnicity, race, medical coverage, body mass index, primary cause of ESRD, employment, primary modality, and access type.

Average Lab Values Prior to Dialysis (7n-7q)

Lines 7n through 7q report lab values prior to start of ESRD. We estimated the glomerular filtration rate (GFR) reported in line 7q using a formula developed by the Modification of Diet in Renal Disease (MDRD) Study (Levey et al, 1999) — a formula based on serum creatinine before first dialysis, age, race, and gender.

Nephrologist Care Prior to Start of ESRD Therapy (7r-7s)

Line 7r reports the percentage of incident patients in 7a who have received an ESA prior to ESRD. Line 7s gives the percentage of patients in 7a who had been under the care of a nephrologist prior to the start of ESRD therapy by categories of time (never, <6 months, 6-12 months, >12 months, unknown).

Kidney Transplant Options (7t-7v)

Line 7t reports the percentage of patients in 7a who had been informed of transplant options. Line 7u gives the count of patients who were not informed of their transplant options. The reasons for not informing the patients reported in 7u of their transplant options (due to being medically unfit, unsuitable due to age, psychologically unfit, declining the information, or not yet being assessed) are reported in line 7v.

Comorbid Conditions (7w-7x)

Line 7w reports the percentage of patients in your facility with each of the comorbid conditions (measured before the start of dialysis) listed. The 2005 changes in Form CMS-2728 have affected the cardiac and diabetes listings; note that 'Ischemic Heart Disease' and 'Myocardial Infarction' are included in *Atherosclerotic Heart Disease (ASHD)*, and 'Cardiac Arrest', 'Cardiac Dysrhythmia', and 'Pericarditis' are included in *Other Cardiac Disease*.

Line 7x gives the average number of comorbid conditions reported per new patient in your facility, your state, your Network, and the nation.

XI. Summaries for All Dialysis Patients Treated as of December 31 of Each Year, 2003-2006

Table 8 summarizes the characteristics of dialysis patients treated on December 31, 2003-2006 in your facility, with corresponding average values for 2006 among patients in your state, ESRD Network, and the U.S.

Patients Treated on 12/31 of Year (8a)

Row 8a reports the total number of dialysis patients treated in your facility on December 31 of each year, according to the conventions described in Section III. We based the summaries of the patient characteristics in Table 8 on the patient population count in this row.

Age (8b, 8c)

We determined age as of December 31 for each patient for each year. We reported the average age and the percentage of patients in each of several age ranges.

Female (8d)

Line 8d reports the percentage of female patients.

Race (8e)

We established each patient's race using two sources of information: the Medical Evidence Form and Standard Information Management System (SIMS). We reported the percentage of patients in each of five race categories: Asian/Pacific Islander (includes Indian sub-continent), African American, Native American (includes Alaskan Native), White (includes Middle Eastern and Arabian), and a combined group for other/unknown/missing race. The 'other/unknown/missing race' category includes patients for whom none of the other race categories was indicated on any of the above sources.

Ethnicity (8f)

We obtained the ethnicity of patients from the CMS Medical Evidence Form, and supplemented it with the ESRD Clinical Performance Measures data sample when available. We reported the percentage of patients in the Hispanic and Non-Hispanic categories.

Cause of ESRD (8g)

We ascertained each patient's cause of ESRD using two sources of information: the Medical Evidence Form and Standard Information Management System (SIMS). We reported the percentage of patients in each of five major cause groups: diabetes; hypertension; glomerulonephritis; other/unknown; and missing cause.

Duration of ESRD (8h, 8i)

We calculated the number of years since first renal replacement therapy for each patient treated in your facility on December 31 of each year. Row 8h reports the average number of years of prior ESRD therapy. Row 8i displays ranges of years since start of ESRD and the corresponding percentages of patients per range.

Nursing facility patients (8j)

We obtained the nursing facility history of patients from the Nursing Home Minimum Dataset. We reported the percentage of patients treated on December 31 of each year that were also treated at a nursing facility at any time during the year.

Modality (8k)

Line 8k reports the primary dialysis modality of patients on chronic dialysis treatment at your facility.

XII. Comorbidities Reported on Medicare Claims for Medicare Dialysis Patients Treated as of December 31 of Each Year, 2003-2005

Table 9 reports comorbid conditions identified on Medicare claims for patients treated on December 31, 2003-2005 in your facility, with corresponding average values for 2005 among patients in your state, Network, and the U.S.

Patients Treated on 12/31 of Year (9a)

Row 9a reports the total number of Medicare dialysis claims with comorbidities listed for patients treated in your facility on December 31 of each year, according to the conventions described in Section III. We based the summaries of the patient characteristics in Table 9 on the patient population count in this row.

Comorbid Conditions (9b)

Line 9b reports the percentage of claims for patients in your facility with each of the comorbid conditions listed.

Average Number of Comorbid Conditions (9c)

Line 9c reports the average number of the comorbid conditions listed in 9b on Medicare claims for patients in your facility.

XIII. How Patients Were Assigned to This Facility and End of Year Patient Status, 2003-2006

An important purpose of this report is to provide and seek feedback on the quality of these data. Much of this report relies on a reasonably accurate and complete description of the patients being treated in each facility at a particular point in time. We believe the overall results warrant a high level of confidence in the assignment of patients to providers. The UM-KECC will continue its efforts to measure and improve the quality of all data presented in this report through comparisons with other available data sources.

Number of Patients Placed in Facility (10a)

Line 10a gives the total number of patients who have been placed in your facility for the mortality summary according to the conventions described in Section III. This number is identical to 1a — the number of patients included in the mortality summaries.

Initial Patient Placement for the Year in This Facility (10b)

Patients entered your facility in one of three ways: as a continuing patient from the previous year; as new to dialysis this year at your facility; as a transfer into the facility

during the year. Item 10b reports the percentage of patients who entered your facility each way. We considered a patient who initiated dialysis treatment at one facility and then transferred to another later that year as both new to dialysis at the first facility and transferred into the facility for the second. We considered patients returning to dialysis after transplant as a transfer into the facility.

Patient Status at End of Year (10c)

Item 10c reports the status at year's end for each patient who was placed in your facility. The categories include patients who were alive and receiving treatment in your facility, who were alive and receiving treatment in another facility, who received a transplant, who died and whose death was attributed to your facility, and who died and whose death was attributed to another facility, as well as all other patients. 'Other patients' includes those who recovered renal function, who discontinued dialysis, or who were lost to follow-up. It also includes dialysis-unrelated deaths. For the purposes of this report's mortality calculations, we did not attribute dialysis-unrelated deaths to any facility.

XIV. Patient and Staff Counts from Annual Facility Survey (Form CMS 2744), 2003-2006

Table 11 reports patient counts according to the Annual Facility Survey (Form CMS-2744). This information was self-reported by the facilities. We report the number of patients who were treated during each year in your facility from 2003-2006, and we show regional averages for 2006 for comparison.

Patients Treated during the Year (11a-11d)

Line 11a reports the number of patients who were treated during each year. Lines 11b-11d report the percentage of these patients who were incident, transferred into your facility, and transferred out of your facility during each year. These numbers include both outpatient and home dialysis patients.

Patients Treated as of 12/31 (11e-11g)

Line 11e reports the number of patients who were treated as of December 31 of each year. Line 11f reports patient modality counts. Line 11g reports the percentage of these patients who had Medicare coverage, had a Medicare application pending, or were non-Medicare patients.

Staffing (11h-11i)

Staffing information was collected in the Annual Facility Survey beginning in 2004. Line 11h reports the total number of full and part time staff positions at the facility as of December 31 of the year. This includes positions that were opened but not filled on this date. Line 11i reports the number of positions in line 11h broken down by type of position. For the purposes of the Annual Facility Survey, a full time position is defined as a position with at least 32 hours of employment a week and a part time position is defined as a position with less than 32 hours of employment a week. In this report, nurses include

all staff holding a registered nurse, licensed practical nurse, vocational nurse, or an advanced practical nurse degree.

XV. Survey and Certification Activity, 2007

Table 12 reports the latest survey and certification information for this facility as of June 2007. We obtained this data from Online Survey Certification and Reporting (OSCAR).

Date and type of last survey (12a, 12b)

Line 12a reports the date of the most recent survey, and line 12b reports the type of survey. The type can be an initial survey, a recertification survey, or a termination survey.

Compliance condition after last survey (12c)

Line 12c reports the compliance condition after the last survey. The possible values are: meets requirements, acceptable plan of correction, or does not meet requirements.

Deficiencies cited at last survey (12d, 12e)

Line 12d reports the number of condition for coverage (CfC) deficiencies cited during the last survey and separately reports the number of standard deficiencies cited during the last survey. Line 12d includes summary of these numbers using surveys from 2003-2007 in this state, ESRD Network, and the nation. Line 12e reports each of the eleven CfC deficiencies separately and includes a summary reporting the percent of surveys citing each deficiency between Jan 2003 and June 2007 in this state, Network, and the nation.

XVI. Facility Information, 2007

Table 13 reports the ownership type, organization name, initial Medicare certification date, number of stations, and types of services provided by the facility as of June 2007. These data were obtained from SIMS as of June 2007. Other provider numbers from which data have been included in this report and any National Provider Identifier (NPI) information for these provider numbers are also listed in this table.

XVII. Please Give Us Your Comments

We welcome questions or comments about this report's content, or any suggestions you might have for future reports of this type. Improvements in the content of future reports will depend on feedback from the nephrology community. Comments can be submitted to www.ArborResearch.org/esrdmeasures until September 10, 2007. If you have questions after the comment period is over, please contact The University of Michigan Kidney Epidemiology and Cost Center (UM-KECC) directly by email, fax, or mail. Please note "2007 Dialysis Facility Reports" as the topic of your correspondence, and include your contact information and facility's Medicare provider number.

UM-KECC

315 West Huron, Suite 240

Ann Arbor, MI 48103

(734) 998-6611 (phone)

(734) 998-6620 (fax)

keccdf@umich.edu (email pertaining to DFR)

www.sph.umich.edu/kecc

References

Andersen PK, Borgun O, Gill RD, Keiding N. *Statistical Models Based on Counting Processes*. New York: Springer-Verlag; 1993. See pages 334 and 406-407.

Collett D. *Modeling Survival Data in Medical Research*. London, England: Chapman and Hall; 1994. See page 153, equation 5.6, and page 151, equation 5.1.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999; 130(6):461-470.

NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy. National Kidney Foundation. *Am J Kidney Dis*. 1997 Sep; 30 (3 Suppl 2): S15-66.

NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. *Am J Kidney Dis*. 1997 Oct;30(4 Suppl 3):S192-240.

NKF-KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2000. *Am J Kidney Dis*. 2001 Jan; 37 (1 Suppl 1): S7-S64.

NKF-KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. *Am J Kidney Dis*. 2001 Jan;37(1 Suppl 1): S182-238.

NKF-DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: Update 2006. *Am J Kidney Dis*. Volume 48, Supplement S1 (July 2006) pages S2-S90

NKF-DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2006. *Am J Kidney Dis*. Volume 47, Supplement S3, Pages 146-146 (May 2006):

SAS Institute Inc. 2004. *SAS/STAT 9.1 User's Guide*. Cary, NC: SAS Institute Inc.: 3213-3329.

Turenne MN, Loos ME, Port FK, Emmert G, Hulbert-Shearon TE, Wolfe RA, Levine GN, Daugirdas JT, Agodoa LYC, Held PJ. The impact of deaths due to AIDS, accidents, and street drugs on standardized mortality ratios (SMRs) by facility. U.S. Renal Data

System and University of Michigan, Ann Arbor. Poster presented at the American Society of Nephrology, New Orleans, LA, November 1996. Abstracts – *J Am. Soc Nephrol* 1996;7:1467.

U.S. Renal Data System, *USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.

Wolfe RA, Gaylin DS, Port FK, Held PJ, Wood CL. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. *Kidney Int* 1992; 42: 991-96.

Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, Held PJ, Port FK: Comparison of mortality in all patient on dialysis, patients awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med* 1999; 341: 1725-1730.

Wolfe RA, Ashby VB, Port FK.1993 DMMS comorbidity index validated by Medical Evidence Form data. *J Am Soc Nephrol* 2001; 11:247A.